Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was held up by the regulator. The FDA has cleared ...

Johnson & Johnson’s seltorexant is one of two new therapies that the company reckons could become blockbuster treatments for depression, and data from a phase 3 trial keeps that hope alive.

Background: Dextromethorphan (DM), the d-isomer of the codeine analog levorphanol, is an active ingredient present in a variety of cough and cold remedies. Recently, data generated from a study in ...

The campaign will feature imagery and video creative across digital retail, owned media, out-of-home placements and paid social over all platforms. TEL AVIV, Israel, March 03, 2025 (GLOBE ...

After hours: March 10 at 6:31:15 p.m. EDT Loading Chart for AXSM ...